ADNI4 (Alzheimer's Disease Neuroimaging Initiative 4) Protocol

Purpose

The ADNI4 (Alzheimer's Disease Neuroimaging Initiative 4) Protocol is the fifth wave of a North American multicenter observational study launched in 2004, sponsored by the National Institute on Aging and the National Institutes of Health. The primary goal of this study is to discover, optimize, standardize, and validate clinical biomarkers used in Alzheimer's disease research and clinical trials. This study seeks to enroll individuals ages 55-90, willing and able to undergo yearly test procedures including cognitive tests, questionnaires, brain imaging, blood draws, and spinal taps. Eligible individuals may have normal cognition with no memory concerns, or have memory concerns and diagnosis of mild cognitive impairment or dementia due to Alzheimer’s disease. Participants will be evaluated on a yearly basis, for 2 to 4 years. 

(PI: Maryam Beigi, MD, Easton Center's Katherine and Benjamin Kagan Alzheimer's Disease Treatment Development Program)

Contact: Lorena Macias at (310) 794-6191 or send an email to LorenaMacias@mednet.ucla.edu to participate in this study or for more information. 

English PDF  

Sponsor: University of Southern California

ClinicalTrials.gov Identifier: NCT02854033

Condition: 

Mild Cognitive Impairment (MCI)
Alzheimer's Disease (AD)

Study Type: Observational

Study Design: 

Observational Model: Cohort
Time Perspective: Prospective

Official Title: Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

Length of Study: Participants will be evaluated on a yearly basis, for 2 to 4 years.

Source: ClinicalTrials.gov

Ages Eligible for Study: 55 Years to 90 Years

Genders Eligible for Study: Both


ADRC-BIND

Study Title: ADRC-BIND (Alzheimer's Disease Research Center - Biomarkers in Neurodegenerative Disease)

Purpose

ADRC-BIND (Alzheimer's Disease Research Center - Biomarkers in Neurodegenerative Disease) is the main observational study supporting various research projects within the Easton Center. The purpose of ADRC-BIND is to collect a large amount of information from tests of brain function and cognitive performance over a period of time to help researchers learn more about and develop new therapies for neurodegenerative diseases. This study seeks to enroll participants willing to undergo cognitive testing, brain imaging (PET and MRI), blood draws, optional lumbar puncture, and an overnight sleep study or 2-hour electroencephalogram (EEG). Eligible participants may have normal cognition or be diagnosed with mild cognitive impairment, Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease with dementia, frontotemporal dementia, primary progressive aphasia, progressive supranuclear palsy, corticobasal degeneration, transient epileptic amnesia, or adult-onset epilepsy. Participants will be evaluated for as long as they are willing and able to participate.

(Principal Investigator: Keith Vossel, MD, MSc)

Contact: Sydney Kilgore at (310) 825-3198 or Skilgore@mednet.ucla.edu, or Katy Figueroa at (310) 206-8993 or KAFigueroa@mednet.ucla.edu to participate in this study or for more information.

English PDF  


ALLFTD

Study Title: ALLFTD (ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration)

Purpose

ALLFTD (ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration) is a multicenter study aimed at clarifying the changes in brain function that result from Frontotemporal Lobar Degeneration (FTLD) syndromes. This study is an extension of two earlier projects, now combined into the largest study on these disorders in the U.S. The purpose of ALLFTD is to understand brain syndromes associated with the deposition of certain abnormal proteins in the frontal lobes and related structures. These syndromes include behavioral variant frontotemporal dementia, primary progressive aphasia, progressive supranuclear palsy, and corticobasal syndrome. All persons with these syndromes are eligible for participation in this study. ALLFTD is composed of two parts. The first and main part is a longitudinal evaluation of the brain changes associated with these FTLD syndromes. Participants undergo clinical and neurological examinations, blood studies, and magnetic resonance imaging (MRI). The main evaluation is at the beginning with yearly visits thereafter. The second is a biofluid study that involves a one-time visit for measuring biomarkers in blood and cerebrospinal fluid. Ultimately, ALLFTD hopes to understand the FTLD syndromes sufficiently to lead to drug trials and other interventions.

More information on ALLFTD is available at https://www.allftd.org/sites.

Contact: Diana Chavez at dianachavez@mednet.ucla.edu or Dr. Mario F. Mendez at mfmendez@mednet.ucla.edu to participate or for more information.

English PDF  


Dementia Research Focus Group

Study Title: The Harbor-UCLA and UCLA Medical Center Research Focus Group Study

Purpose

The Harbor-UCLA and UCLA Medical Center Research Focus Group Study is a focus group study for participants with Mild Cognitive Impairment (MCI), mild Alzheimer’s Disease (AD), an AD related dementia (ADRD), or caregivers for someone with memory changes, mild cognitive impairment, or mild dementia. We are looking for people who are interested in participating in a focus group conversation with others that will take place in person in the Los Angeles area. Study procedures may include:
Answering questions about yourself, hearing your thoughts on research, and discussing different types of research.

  • Duration: One-time participation, with 1 visit
  • Requirements to participate in the study include:
    • Diagnosis of mild cognitive impairment (MCI)/mild dementia as determined by the referring provider OR Caregiver of an individual with a dementia
    • 18 years or older
    • Able to attend a focus group for about 1.5 hours
    • Speak and read English and/or Spanish

(PI: Timothy Chang, MD, PhD)

To learn more, please contact Ariadna Martinez at (310) 206-0468 or by email at adrceaston@mednet.ucla.edu.

English PDF  


DREAM-LA

Study Title: The Dementia Research, Education, and Advancement in Los Angeles (DREAM-LA) Study

Purpose

The Dementia Research, Education, and Advancement in Los Angeles (DREAM-LA) study is an observational, tiered participation study for participants with Mild Cognitive Impairment (MCI), Alzheimer’s Disease (AD), an AD related dementia (ADRD), or cognitively normal control. We are looking for people who are Hispanic/Latino (HL), Black/African American, or Asian American, Native Hawaiian Pacific Islander (AANHPI). The are multiple levels of participation that are available. Study procedures may include: Medical exam, Survey about social factors, Genetic counseling, Cognitive test, Brain MRI (an image of the brain), Blood draw, and 2-hour brain wave study.

  • Duration: One-time participation, with 1-2 visits
  • Requirements to participate in the study include:
    • Age: 50 and older
    • Have a diagnosis of Mild Cognitive Impairment (MCI), Alzheimer’s Disease (AD), an AD related dementia (ADRD), or cognitively normal control
    • Self-report as Hispanic/Latino (HL), Black/African American, or Asian American, Native Hawaiian Pacific Islander (AANHPI)

(PI: Keith Vossel, MD, MSc)

To learn more, please contact Sydney Kilgore at (310) 825-3198 or by email at Skilgore@mednet.ucla.edu, Katy Figueroa at (310) 206-8993 or by email at KAFigueroa@mednet.ucla.edu, or Karen Elrayes at (310) 206-1822 or by email at KElrayes@mednet.ucla.edu.

English PDF   Spanish PDF 


FTD Hate Study

Study Title: The Relationship of Hate to Dehumanization: An Exploration in Neurotypical and Frontotemporal Dementia

Purpose

The UCLA Neurology Department is conducting a study part of the cohort at the Institute to Study Hate. The primary purpose of this study is to better understand the functioning of hate. This will lead to a better understanding and mitigation of group-based hate. This study seeks to enroll individuals ages 18-65, willing to complete 2-3 hours of online or in-person testing consisting of viewing videos and responding to questionnaires. Persons with Frontotemporal Dementia have additional testing and review of prior brain scans.

(PI: Mario F. Mendez, MD, PhD)

Contact: Alexander Sheppard at ASheppard@mednet.ucla.edu or Dr. Mario F. Mendez at mfmendez@mednet.ucla.edu to participate or for more information.

English PDF  


MUSIC

Study Title: MUSIC (Music Stimulation to Improve Cognition)

Purpose

MUSIC (Music Stimulation to Improve Cognition) is an exploratory study aimed at understanding how 40-Hz enhanced music and light can impact brain functioning. This study seeks to enroll participants willing to undergo electroencephalogram (EEG) while listening to 40-Hz enhanced music. Eligible participants may have normal cognition or be diagnosed with mild cognitive impairment, Alzheimer’s disease, or dementia with Lewy bodies. Participants will be required to come in for one study visit or, if enrolled in ADRC-BIND, stay an additional hour after their overnight sleep study. 

(PI: Keith Vossel, MD, MSc)

Contact: Karen Elrayes at (310) 206-1822 or KElrayes@mednet.ucla.edu to participate in this study or for more information.

 


NIA-AD FBS

Study Title: NIA-AD FBS (National Institute on Aging - Alzheimer’s Disease Family Based Study)

Purpose

NIA-AD FBS (National Institute on Aging - Alzheimer’s Disease Family Based Study) is a longitudinal observational study recruiting families with multiple members diagnosed with Alzheimer’s disease (AD) or related disorders for genetic research. The study seeks to enroll families with 3+ individuals willing to participate. For families to be included, at least one sibling must have an established diagnosis of AD or have a diagnosis of a related disorder such as frontotemporal dementia or dementia with Lewy bodies. The family will also require an informant. Those who choose to participate in this study will undergo cognitive testing, MRIs, and blood draws every 18 months for up to 5 years. 

(PI: Keith Vossel, MD, MSc)

Contact: Sydney Kilgore at (310) 825-3198 or Skilgore@mednet.ucla.edu, or Katy Figueroa at (310) 206-8993 or KAFigueroa@mednet.ucla.edu to participate in this study or for more information.